For drug development
Find your next patients before your competitors do.
For pharma, biotech, SMEs, drug-development companies, universities and research groups.
Cytogent shows you where resistant-cancer patients are, who will be ready for your study and when, and lets you reach the hospitals that care for them, directly.
What you get
Know where your next patients will be.
Live view of resistant-cancer populations
Anonymised groups of patients by cancer type, biomarkers, prior treatments and resistance status, across a growing network of European hospitals.
Forecasts, not snapshots
See how many patients are likely to become eligible over the coming months, and at which sites. Plan enrolment on what’s coming, not only on what exists today.
Recommendations for your next step
Our models highlight under-served resistant populations and the study designs hospitals are ready to run, so you can choose where to invest next.
Patient groups ready for your study
Hospitals mark patients who are open to research. You see how many match your criteria.
Apply directly to hospitals
Send a study request with your criteria, timeline, budget and support. Hospitals accept, open a discussion, or decline, and you see why.
Faster feasibility
Answers in weeks instead of months, based on real patient data rather than questionnaires.
Why drug developers choose Cytogent
Where tomorrow’s studies happen.
Resistance is our focus
Patients who progress on today’s therapies are where tomorrow’s studies happen. We are built around them.
Hospitals want to work with us
Our platform helps clinicians every day, so sites are engaged, not just listed.
Predictive, not static
Know who will be eligible, not only who was.
European by design
Access to European cancer centres, built for European privacy and data rules.
Open to every innovator
From global pharma to university groups and small biotechs.
For academic and research groups
Investigator-initiated studies are welcome.
Running an investigator-initiated study or a translational project? Cytogent connects you with hospitals and suitable patient groups on terms that fit academic budgets.
Questions
Quick answers.
Can we see patient-level data?
No. You see anonymised groups and forecasts. Contact with patients happens only through their own clinicians and with consent.
How fast can we start?
A first feasibility view can be ready within weeks of agreeing your criteria.
How is it priced?
Flexible: subscription, per study, or per site. Let's talk.
Who can apply?
Pharma, biotech, SMEs, drug-development companies, universities and research groups. Academic groups get terms that fit academic budgets.
How do study requests work?
You send a request with your criteria, timeline, budget and support. The hospital accepts, opens a discussion or declines, and you see why.
